Selective MEK inhibitor (Ki
= 300 nM in vitro
). Suppresses FGF-mediated angiogenesis in vivo
and decreases VEGF expression. Enhances the therapeutic efficacy of taxol
(Cat. No. 1097) in vivo
. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
CI-1040 (PD184252), a targeted signal transduction inhibitor of MEK (MAPKK).
Allen et al.
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid et al.
Cancer Res., 2005;65:2854
BRAF mutation predicts sensitivity to MEK inhibition.
Solit et al.
The citations listed below are publications that use Tocris products. Selected citations for PD 184352 include:
Showing Results 1 - 3 of 3